VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

Kronos Bio, Inc. Executive Compensation (FY23)

KRON · Executive and director compensation, fiscal 2022 to 2023
Chief executive, fiscal 2023
◇
Norbert Bischofberger
Latest say-on-pay support
=
June 25, 2024
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The Kronos Bio, Inc. brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 27, 2024
3 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Kronos Bio, Inc. brief$500Get the executive brief
Velarion Intel, one year, every company
115 figures on this page: 113 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
What changed from fiscal 2022 to fiscal 2023
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Norbert Bischofberger: $2,796,660 → $1,761,537 (37.0% lower)
Say-on-pay support: 98.7% → 97.4% (1.3 points lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Kronos Bio, Inc.'s chief executive and what were they paid?
Norbert Bischofberger, President and Chief Executive Officer, received $1,761,537 in total compensation for fiscal 2023. Compared with the $2,796,660 reported for fiscal 2022, Bischofberger's total was 37.0% lower.
What was Kronos Bio, Inc.'s say-on-pay result?
For fiscal 2023, shareholders backed the say-on-pay proposal with 97.4% of votes cast for or against in favor at the meeting held June 25, 2024.
Which companies are in Kronos Bio, Inc.'s peer group?
The disclosed peer group names Allogene Therapeutics, Inc., ALX Oncology Holdings Inc., Ambrx Biopharma Inc., AnaptysBio, Inc. and C4 Therapeutics, Inc., among others.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Norbert Bischofberger
President and Chief Executive Officer
◇——◇◇—◇◇
Jorge DiMartino
Former Chief Medical Officer and Executive Vice President, Clinical Development
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Norbert Bischofberger
President and Chief Executive Officer
◇——◇◇—◇◇
Barbara Kosacz
Former Chief Operating Officer and General Counsel
Departed during or after this year
◇◇◇◇◇—◇◇
Jorge DiMartino
Former Chief Medical Officer and Executive Vice President, Clinical Development
Departed during or after this year
◇◇◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2023
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Norbert BischofbergerRSU◇——◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2023 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Norbert BischofbergerOption◇—◇2/15/2033
Option◇—◇2/16/2032
Option◇—◇12/10/2030
RSU◇◇——
Jorge DiMartinoOption◇—◇12/2/2029
Option◇—◇2/15/2033
RSU◇◇——
Option◇—◇12/9/2030
Option◇—◇2/15/2032
RSU◇◇——
Barbara KosaczOption◇—◇2/15/2033
RSU◇◇——
Option◇—◇2/15/2032
RSU◇◇——
RSU◇◇——
Option◇—◇12/9/2030
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2023
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Arie Belldegrun, M.D., FACS
◇—◇———◇
Katherine Vega Stultz
◇—◇———◇
Roger D. Dansey, M.D
◇—◇———◇
Elena Ridloff, CFA
◇◇◇———◇
Taiyin Yang, Ph.D
◇—◇———◇
Roshawn Blunt
◇—◇———◇
David M. Tanen
◇—◇———◇
Joshua Kazam
◇—◇———◇
Marianne De Backer, Ph.D
◇—◇———◇
Otella Stampacchia
◇—————◇
Otellla Stampacchia, Ph.D
◇—————◇
Norbert Bischofberger, Ph.D served on the board in fiscal 2023 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options/Rsus.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2023
  • Allogene Therapeutics, Inc. ALLO
  • ALX Oncology Holdings Inc. ALXO
  • Ambrx Biopharma Inc. symbol not shown
  • AnaptysBio, Inc. ANAB
  • C4 Therapeutics, Inc. CCCC
  • Gossamer Bio, Inc. GOSS
  • Gritstone bio, Inc. GRTS
  • IGM Biosciences, Inc. IGMS
  • iTeos Therapeutics, Inc. ITOS
  • Jounce Therapeutics, Inc. JNCE
  • Kura Oncology, Inc. KURA
  • Mersana Therapeutics, Inc. MRSN
  • Nkarta, Inc. NKTX
  • Nurix Therapeutics, Inc. NRIX
  • Prelude Therapeutics, Incorporated PRLD
  • Rain Oncology, Inc. symbol not shown
  • RAPT Therapeutics, Inc. RAPT
  • Replimmune Group, Inc. REPL
  • Rubius Therapeutics, Inc. RUBY
  • Scholar Rock Holding Corporation SRRK
  • Surface Oncology, Inc. symbol not shown
  • Syndax Pharmaceuticals, Inc. SNDX
  • TCR2 Therapeutics, Inc. TCRR
  • Verastem, Inc. VSTM

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2023June 25, 2024=◇◇◇
2022June 22, 2023=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Norbert Bischofberger (President and Chief Executive Officer), FY2023 total compensation $1,761,537 (base salary $580,000) [exec_comp, SEC accession 0001140361-24-023006, filed 2024-04-29]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Kronos Bio, Inc. files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Kronos Bio, Inc. disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Kronos Bio, Inc. sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Kronos Bio, Inc.'s disclosed peer group is defensible, who names Kronos Bio, Inc. back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
115 figures on this page: 113 cited to the filing that reported them, 2 calculated from figures it prints.
113 cited to the filing
2 calculated from the filing

Documents cited

  1. 0001140361-24-031561
  2. 0001140361-24-023006
    2023 Summary Compensation Table · Non-Employee Director Compensation Policy · Outstanding Equity Awards at Fiscal Year-End Table
  3. 0001741830-23-000041
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Kronos Bio, Inc. executive compensation, FY2022–FY2023.” https://intel.velarion.ai/comp/KRON (accessed 2026).
Short form: data: Velarion

The Kronos Bio, Inc. brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Kronos Bio, Inc. and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Kronos Bio, Inc. discloses

The companies named in KRON's own disclosed peer group.

Allogene Therapeutics, Inc.ALX Oncology Holdings Inc.AnaptysBio, Inc.C4 Therapeutics, Inc.Gossamer Bio, Inc.IGM Biosciences, Inc.iTeos Therapeutics, Inc.Kura Oncology, Inc.Mersana Therapeutics, Inc.Nkarta, Inc.Nurix Therapeutics, Inc.Prelude Therapeutics, IncorporatedRAPT Therapeutics, Inc.Replimmune Group, Inc.Scholar Rock Holding CorporationSyndax Pharmaceuticals, Inc.Verastem, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy